Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

370 ARTÍCULOS , VIENDO DEL 151 AL 165

Comparison of multiple interventions for older adults with Alzheimer disease or mild cognitive impairment: A PRISMA-compliant network meta-analysis

Liang JH, Xu Y, Lin L, Jia RX, Zhang HB, Hang L.

Medicine (Baltimore). 2018 May;97(20):e10744. doi: 10.1097/MD.0000000000010744.

Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer's disease

Jabir NR, Khan FR, Tabrez S.

CNS Neurosci Ther. 2018 Sep;24(9):753-762. doi: 10.1111/cns.12971. Epub 2018 May 16.

Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors

Grossberg GT, Alva G, Hendrix S, Ellison N, Kane MC, Edwards J.

Alzheimer Dis Assoc Disord. 2018 Jul-Sep;32(3):173-178. doi: 10.1097/WAD.0000000000000261.

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A.

J Control Release. 2018 Jul 10;281:139-177. doi: 10.1016/j.jconrel.2018.05.011. Epub 2018 May 24.

Marine derived bioactive compounds for treatment of Alzheimer's disease

Lakshmi S, Prakash P, Essa MM, Qoronfleh WM, Akbar M, Song BJ, Kumar S, Elumalai P.

Front Biosci (Elite Ed). 2018 Jun 1;10(3):537-548. doi: 10.2741/E840.

Caffeine: A Potential Protective Agent Against Cognitive Decline in Alzheimer's Disease

Hussain A, Tabrez ES, Mavrych V, Bolgova O, Peela JR.

Crit Rev Eukaryot Gene Expr. 2018;28(1):67-72. doi: 10.1615/CritRevEukaryotGeneExpr.2018021391.

A comparative study of EPA-enriched ethanolamine plasmalogen and EPA-enriched phosphatidylethanolamine on Aβ(42) induced cognitive deficiency in a rat model of Alzheimer's disease

Che H , Li Q , Zhang T , Ding L , Zhang L , Shi H , Yanagita T , Xue C , Chang Y , Wang Y .

Food Funct. 2018 May 23;9(5):3008-3017. doi: 10.1039/c8fo00643a.

Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease

Ryan P, Patel B, Makwana V, Jadhav HR, Kiefel M, Davey A, Reekie TA, Rudrawar S, Kassiou M.

ACS Chem Neurosci. 2018 Jul 18;9(7):1530-1551. doi: 10.1021/acschemneuro.8b00185. Epub 2018 Jun 26.

The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing

Blaszczyk AT, Mang BH, Garza H, Mathys M.

Consult Pharm. 2018 May 1;33(5):273-282. doi: 10.4140/TCP.n.2018.273..

Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis

Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, Pan Z, Mansur RB, McIntyre RS.

Diabetes Obes Metab. 2018 Oct;20(10):2467-2471. doi: 10.1111/dom.13373. Epub 2018 Jun 19.

Role of p38/MAPKs in Alzheimer's disease: implications for amyloid beta toxicity targeted therapy

Kheiri G, Dolatshahi M, Rahmani F, Rezaei N.

Rev Neurosci. 2018 Dec 19;30(1):9-30. doi: 10.1515/revneuro-2018-0008.

Apelin, a promising target for Alzheimer disease prevention and treatment

Masoumi J, Abbasloui M, Parvan R, Mohammadnejad D, Pavon-Djavid G, Barzegari A, Abdolalizadeh J.

Neuropeptides. 2018 Aug;70:76-86. doi: 10.1016/j.npep.2018.05.008. Epub 2018 May 23.

Oxidative Stress in Elderly with Different Cognitive Status: My Mind Project

Fattoretti P, Malavolta M, Fabbietti P, Papa R, Giacconi R, Costarelli L, Galeazzi R, Paoloni C, Postacchini D, Lattanzio F, Giuli C.

J Alzheimers Dis. 2018;63(4):1405-1414. doi: 10.3233/JAD-171117.

Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review)

Hassan M, Abbas Q, Seo SY, Shahzadi S, Al Ashwal H, Zaki N, Iqbal Z, Moustafa AA.

Mol Med Rep. 2018 Jul;18(1):639-655. doi: 10.3892/mmr.2018.9044. Epub 2018 May 22.

The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update

Khoury R, Grysman N, Gold J, Patel K, Grossberg GT.

Expert Opin Investig Drugs. 2018 Jun;27(6):523-533. doi: 10.1080/13543784.2018.1483334. Epub 2018 Jun 18.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias